China: Boray Data raises Series B; Tiansheng Pharma valuation rises to $986m

China: Boray Data raises Series B; Tiansheng Pharma valuation rises to $986m

Chinese companies are still actively raising fund through both specialised investment firms and the capital market. Boray Data, a Big Data company, has completed a Series B round worth tens of millions of dollars from CASH Capital and other investors. Meanwhile, Tiansheng Pharmaceutical, a private equity-backed company, listed its shares on the Shenzhen Stock Exchange on May 19 and is valued at about $986 million.

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter